Murray, Frank & Sailer has filed a class action suit in the Southern District of Texas Houston Division, against Repros Therapeutics and some of its officers and directors.
Warner Chilcott’s revenue in the quarter ended June 30, 2009 increased 7.1% to $250.8m over the prior year quarter. The company reported net income of $56m, or $0.22
For the quarter ended June 30, 2009, Catalyst reported a net loss of $1.76m, or $0.13 per basic and diluted share, compared to a net loss of $2.37m,
MediGene, in co-operation with the British drug regulatory authority – Medicines and Healthcare Products Regulatory Agency, has conducted a series of in-vitro studies to rule out any potential
Antisoma has reported that the phase II trial of AS1402 in breast cancer is to be discontinued. This follows a meeting of the trial’s Data Monitoring Committee (DMC)
Opexa Therapeutics has entered into an agreement with Novartis for the further development of its novel stem cell technology. The technology, which has generated preliminary data showing the
Oculus Innovative Sciences reported total revenue of $1.8m in the first quarter of FY2010, an increase of 52% over $1.2m in the first quarter of fiscal 2009. Product
The European Commission (EC) has approved Afinitor (everolimus) tablets for the treatment of patients with advanced renal cell carcinoma (RCC), whose disease progressed on or after treatment with
Galapagos has completed its first-in-human trial of the novel candidate drug GLPG0259, for rheumatoid arthritis (RA). GLPG0259 is a novel mechanism-of-action inhibitor of the protein – kinase MAPKAPK5,
Curis and Debiopharm have entered into an agreement for Curis’ Heat Shock Protein (Hsp90) technology, including CUDC-305, the company’s lead Hsp90 inhibitor candidate. Under the terms of the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.